Dr. Mark Pegram and Dr. Neil Iyengar – T-DXd’s Rise in HER2+ & HER2-Low Breast Cancer

Playlist - Dr. Mark Pegram & Dr. Neil Iyengar

DB11 and the Role of (T-DXd) in NACT high risk early stage HER2-Positive Breast Cancer

1 min read

The Predictive Power of 11%: Is T-DXd’s pCR Gain Enough for Long-Term Benefit?

1 min read

T-DXd in the DB11 NACT Space: Is De-escalation in adjuvant setting Possible by Maximizing pCR?

1 min read

Safety Profile of Neoadjuvant T-DXd in DB11: Balancing ILD Risk Against Anthracycline Cardiotoxicity

1 min read

Deciphering the T-DXd Dilemma: Dual Success in DESTINY-Breast11 and DESTINY-Breast05

1 min read

Adjuvant ADC Head-to-Head: DB05 Data Define a New Standard in Early HER2-Positive Breast Cancer

1 min read

Managing T-DXd Toxicity: ILD Monitoring and the Curative Risk-Benefit Analysis in DB05

1 min read

How To Approach residual Disease After Neoadjuvant T-DXd

1 min read

DB09: T-DXd + Pertuzumab Challenges the Cleopatra Regimen in First-Line Metastatic Disease

1 min read

Bridging PATINA and DB09: The Evolving Induction Followed by Maintenance Strategy

1 min read